Veraxa Biotech (VRXA) Financial Statements

9 Followers

Veraxa Biotech Financial Overview

Veraxa Biotech's market cap is currently $61.98M. The company's EPS TTM is $0.2496; its P/E ratio is 50.75; Veraxa Biotech is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 25	Dec 24
Income Statement
Total Revenue	$ 0.00	$ 0.00
Gross Profit	$ 0.00	$ 0.00
Operating Income	$ -1.79M	$ -702.96K
EBITDA	$ -1.79M	$ -702.96K
Net Income	$ 8.99M	$ 4.14M
Balance Sheet
Cash & Short-Term Investments	$ 182.10K	$ 668.28K
Total Assets	$ 270.06M	$ 259.81M
Total Debt	$ 0.00	$ 0.00
Net Debt	$ -182.10K	$ -668.28K
Total Liabilities	$ 13.34M	$ 12.08M
Stockholders' Equity	$ 256.72M	$ 247.73M
Cash Flow
Free Cash Flow	$ -486.18K	$ -703.47K
Operating Cash Flow	$ -486.18K	$ -703.47K
Investing Cash Flow	$ 0.00	$ -254.26M
Financing Cash Flow	$ 0.00	$ 255.64M

Currency in USD

Veraxa Biotech Earnings and Revenue History

Income Statement >

Veraxa Biotech Debt to Assets

Balance Sheet >

Veraxa Biotech Cash Flow

Cash Flow >

Veraxa Biotech Forecast EPS vs Actual EPS

Currently, no data available

Please return soon. This page is being updated.

Earnings >